DOI:
10.1055/s-00000134
Diabetologie und Stoffwechsel
LinksClose Window
References
Mosenzon O, Wiviott SD, Cahn A. et al.
Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial.
Lancet Diabetes Endocrinol 2019;
7 (08) 606-617
Access:
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.